Now I have enough to write a well-sourced synthesis. Let me compose the analysis.
---
The single most promising near-term path to field-deployable blight-resistant American chestnuts is The American Chestnut Foundation's recurrent genomic selection (RGS) breeding program. Within the RGS program, TACF is pursuing four parallel breeding tracks: three use backcross hybrid trees to maximize blight resistance, balance gains in blight and Phytophthora root rot (PRR) resistance simultaneously, or maximize PRR resistance, all while maintaining a minimum of 70% American chestnut ancestry, and a fourth non-hybrid track maximizes blight resistance among offspring of large surviving American chestnuts. TACF also preserves regional genetic diversity from remaining wild American chestnut populations to use as the background for producing regionally adapted reintroduction trees that will continue to evolve and survive in a changing world. This genomics-informed approach avoids the single-gene bottleneck that plagued the transgenic strategy and can accelerate selection across multiple resistance loci simultaneously, compressing what would otherwise be many decades of conventional breeding into a faster iterative cycle. Given that multiple quantitative trait loci underlie blight resistance in Chinese chestnut, a polygenic breeding strategy rooted in genomic prediction is almost certainly necessary to produce trees with durable, field-relevant resistance across the species' wide native range.
The most significant recent scientific development is the effective collapse of the Darling 58 transgenic line as a viable restoration vehicle and the complicated pivot to Darling 54. TACF issued a press release discontinuing development of Darling 58. The original January 2020 ESF petition to USDA APHIS referred to Darling 58 instead of Darling 54; these two lines were produced at the same time, using the same transgenes in the same genetic background, so they express the same protein products. The USDA confirms that the petition for deregulation is still pending and that they are waiting for additional information from ESF as to how they want to proceed. Of the 9,289 public comments posted to the docket, the majority were in favor of deregulation of blight-tolerant American chestnut, though many were in opposition, and EPA stated it "did not identify significant environmental concerns to be addressed in the Final EIS." Meanwhile, ESF's research pipeline has moved beyond the original constitutive-promoter Darling design. Their next-generation "DarWin" chestnuts ramp up expression of OxO specifically in response to wounding and blight infection. Additional transformations in the pipeline include OxO driven by a citrus phloem promoter, a germin-like protein gene from chestnut, a laccase gene from Chinese chestnut that may strengthen cell walls, and two RNA interference vectors that could inhibit specific genes in the blight fungus. This matters because it represents a shift from a single-transgene, constitutive-expression paradigm toward a more sophisticated, multi-mechanism, wound-inducible approach that is scientifically more defensible.
The biggest remaining bottlenecks are both regulatory and scientific. On the regulatory side, the Darling 54 deregulation petition remains in limbo at USDA APHIS, with the petition having been complicated by the switch from Darling 58 to Darling 54, and critics arguing that the original petition was premature given that trees had only been in controlled outdoor field trials for three years at the time of submission. A for-profit company, American Castanea, became entangled with the effort, raising governance concerns. The regulatory pathway for any future transgenic or gene-edited chestnut line—whether DarWin or an RNAi construct—will face the same multi-agency (USDA, EPA, FDA) scrutiny, and there is no expedited framework for conservation-purpose genetic engineering of forest trees. On the scientific side, ESF has acknowledged that production and distribution of blight-tolerant trees for restoration is a much bigger task than any one group could attempt alone, and has developed a non-exclusive license structure to facilitate distribution at different scales. The fundamental challenge of scaling from greenhouse-validated resistance to landscape-level restoration across diverse edaphic and climatic conditions remains immense, as does the need to combine blight resistance with PRR resistance and adequate genetic diversity to sustain adaptive evolution over centuries.
New funding would have the highest impact-per-dollar if directed at two priorities. First, expanding TACF's recurrent genomic selection infrastructure—specifically, increasing the capacity for controlled pollinations, genotyping throughput, and the number of field test sites across the species' range—would directly accelerate the breeding cycle that is currently the most realistic path to deployable trees. The RGS cycle involves crossing selected parents, growing offspring, taking DNA samples, using models to identify the top 10% for resistance, and field-testing the rest to refine the model. Each additional cycle and each additional test site improves prediction accuracy and regional adaptation. Second, supporting ESF's next-generation transgenic pipeline, particularly the DarWin wound-inducible constructs and the RNAi vectors, which are being tested alone and in combination with OxO to optimize blight resistance, would maintain the biotechnology option as a complement to breeding. These two tracks are not competitors but complements: transgenic resistance genes validated through the ESF pipeline could eventually be introgressed into the genomically selected breeding populations, combining the speed of genetic engineering with the genetic breadth and adaptability of a well-managed breeding program. The worst allocation of funds at this point would be further investment in the original Darling 58/54 line without resolution of the regulatory and performance questions that have stalled it.